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Abstract
Living donor liver transplantation (LDLT) may have better immunological outcomes compared to
deceased donor liver transplantation (DDLT). The aim of this study was to analyze the incidence
of acute cellular rejection (ACR) after LDLT and DDLT.
Data from the Adult-to-Adult Living Donor Liver Transplantation (A2ALL) Retrospective Cohort
Study on 593 liver transplants done between May 1998 and March 2004 were studied (380 LDLT;
213 DDLT). Median LDLT and DDLT follow-up was 778 and 713 days, respectively. Rates of
clinically treated and biopsy-proven ACR were compared.
There were 174 (46%) LDLT and 80 (38%) DDLT recipients with ≥1 clinically treated episodes
of ACR, whereas 103 (27%) LDLT and 58 (27%) DDLT recipients had ≥1 biopsy-proven ACR
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episode. A higher proportion of LDLT recipients had clinically treated ACR (P=0.052), but this
difference was largely attributable to one center. There were similar proportions of biopsy-proven
rejection (P=0.97) and graft loss due to rejection (P=0.16). Longer cold ischemia time was
associated with a higher rate of ACR in both groups despite much shorter median cold ischemia
time in LDLT.
These data do not show an immunological advantage for LDLT, and therefore do not support the
application of unique post-transplant immunosuppression protocols for LDLT recipients.
INTRODUCTION
The favorable long term graft function and excellent graft survival in the setting of living
donor kidney transplantation is attributed, in part, to selection of transplant candidates,
utilization of organs from pristine donors, recovery of donor organs that have not been
exposed to the stress associated with brain death, and minimization of injuries related to
more prolonged cold ischemia time (1-3). In addition, there might be an immunological
advantage due to HLA matching among biologically related individuals. The end result is
that living donor kidney recipients experience a lower incidence of acute and chronic
allograft rejection compared to recipients of deceased donor kidneys (4, 5). It is logical to
hypothesize that the variables affecting kidney graft survival are attributable in part to a
reduction in the intensity of the early proinflammatory response, and contribute to better
immunological acceptance of the organ. In theory, such an advantage should extend to the
setting of LDLT, in which an excellent liver lobe taken from a stable donor is exposed to a
short period of cold ischemia, and may be placed in selected recipients who may be
genetically related. An additional and potentially important variable in the LDLT setting is
the induction and progression of liver regeneration that occurs in the immediate post-
transplant period. Molecular pathways associated with regeneration may regulate
proinflammation, and consequently, may play a role in the development of the alloimmune
response (6, 7). The sum of these variables may affect alloimmunity, an outcome that may
be measured clinically by the frequency and severity of episodes of acute rejection.
Limited information is available regarding the frequency and severity of acute rejection
episodes in the setting of LDLT. Previous clinical observations are limited to analysis of the
Scientific Registry of Transplant Registry (SRTR) database, which lacks detailed clinical
information about rejection and single center experiences with relatively small numbers of
recipients (8-10). Our prior analysis of the SRTR database suggested a lower rate of
rejection in recipients of LDLT when compared to deceased donor liver transplant (DDLT)
recipients (8). However, a recent validation study comparing A2ALL and SRTR data
demonstrated discrepancies representing missed reporting of LDLT rejection in the SRTR as
reported by centers (11). Other reports indicated a lower rate of rejection in a small number
of LDLT recipients after relatively short-term follow-up (9, 10).
The relevance of this information to the clinical management of this population is clear: a
differential pattern of acute cellular rejection (ACR) in LDLT vs. DDLT that is determined
by suppressed or enhanced alloimmune response in one or the other setting may suggest
procedure-specific immunosuppression management. The aim of the retrospective study
reported here was to determine the incidence of rejection in recipients undergoing LDLT or
DDLT, to examine the rate of recurrent rejection, to determine whether the etiology of the
primary liver disease or other recipient factors were associated with early and/or long-term
rates of acute rejection, and to examine whether rejection was differentially affected by the
use of antibody induction therapy in the two groups.
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Data for this study were derived from the A2ALL Retrospective Cohort Study. Information
was collected from extensive chart reviews, supplemented by data from the SRTR made
available through a data use agreement. The study included 819 subjects who had a potential
living donor evaluated between January 1, 1998 and February 28, 2003 at nine U.S.
transplant centers. Those analyzed relate to the 593 patients who received a transplant: 380
LDLT and 213 DDLT. Potential recipients whose procedures were aborted were not
included. Recipients of domino transplants (n=2) were included in DDLT group. Median
post-transplant follow-up was 778 days for LDLT and 713 days for DDLT recipients,
respectively. There was a range of LDLT and DDLT recipients from A2ALL participating
centers; all centers performed at least 20 LDLT. The use of induction therapy, maintenance
of immunosuppression, and treatment modalities for ACR were not uniform within the
participating centers.
The database included extensive information that documented the time to the first episode of
rejection and recurrent rejection, whether the diagnosis was confirmed by liver biopsy, and
what type of anti-rejection treatment was given. The following rejection definitions were
used. The term clinically treated rejection was used when the diagnosis of rejection was
suspected, and was accompanied by anti-rejection treatment. Such recipients were treated
for rejection with or without confirmation of the diagnosis by liver biopsy. The treatment for
rejection included any of the following options: steroid bolus and/or taper, with or without
administration of antibody therapy. In a very small number of cases (n=8), rejection was
treated with a switch or addition to baseline immunosuppressive drugs. Biopsy-proven
rejection was used when the diagnosis of rejection was suspected, the presence of rejection
was confirmed by liver biopsy, and treatment for rejection was given. The diagnosis of ACR
was confirmed by the local pathologist, and there was no central reading of biopsy slides in
this study.
Statistical Methods
Two-sample t-tests and chi-square tests were used to compare LDLT and DDLT recipients
with respect to baseline characteristics. Chi-square tests were also used to compare the
transplant centers for the proportion of their patients with any clinically treated rejection and
any biopsy-proven rejection. Chi-square tests were used to compare differences between
LDLT and DDLT for the proportion with any clinically treated rejection and any biopsy-
proven rejection. Mantel-Haenszel trend tests were used to compare LDLT vs. DDLT with
respect to the number of clinically treated and biopsy-proven rejection episodes (0, 1, 2, and
more than 2). Time to the first clinically treated rejection and time to the first biopsy-proven
rejection were evaluated by the Kaplan-Meier (KM) method. Unadjusted comparisons
between LDLT and DDLT were made using the log-rank test. Many of these comparisons
were performed both with and without Center A, which had an extreme value for the
proportion with treated rejection.
Cox regression models were used to investigate predictors of time from transplant to the first
biopsy-proven rejection. Covariate effects were presented as adjusted hazard ratios (HR)
with 95% confidence intervals (CI). Analyses of variables associated with biopsy-proven
rejection were not controlled for center effect. Cumulative probabilities of graft failure or
death over time were estimated by the KM method. P-values < 0.05 were considered to be
statistically significant. All analyses were carried out using SAS 9.1 statistical software
(SAS/STAT 9.1 User's Guide, SAS Publishing, Cary, NC: SAS Institute Inc., 2004).
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Human Subjects Protection—The study was approved by the Institutional Review
Boards and Privacy Boards of the University of Michigan Data Coordinating Center and
each of the nine participating transplant centers.
RESULTS
Patient characteristics
Patient characteristics, particularly those previously described to affect the incidence and
severities of ACR, are presented in Table 1. The distributions of recipient age, gender, and
race were similar in the LDLT and DDLT groups. Importantly, proportions with immune-
related disease etiologies known to be associated with post-transplant rejection were similar
in the LDLT and DDLT recipients. Finally, the frequency of antibody induction therapy and/
or maintenance immunosuppression was similar between the groups.
Center-specific incidence of rejection
Clinical practices varied by center. In some centers in this retrospective study, confirmatory
biopsy was obtained in most treated recipients, while empirical treatment without biopsy
was more common in others (Table 2). At one site (Center A), LDLT recipients were
routinely given anti-rejection treatment in the early post-transplant phase with minimal
indications. The center-specific incidence of clinically treated and biopsy-proven rejection
demonstrated significant differences for LDLT and DDLT recipients within the same center,
and between centers (Table 2). These center differences were also significant when Center A
was excluded.
Incidence of clinically treated rejection
A total of 174 (46%) LDLT recipients had at least one clinically treated rejection episode,
compared to 80 (38%) DDLT recipients with at least one clinically treated rejection episode
(P=0.052) (Table 3). A total of 271 clinically treated rejection episodes were reported in
LDLT recipients vs. 105 clinically treated rejection episodes in DDLT recipients. The
majority of these episodes were confirmed by liver biopsy (vide infra). However, some
recipients were clinically treated for the diagnosis of rejection without biopsy. Excluding
center A, the respective numbers (%) of clinically treated rejection episodes were 110/310
(35%) for LDLT and 60/173 (35%) for DDLT (chi-square p=0.86 and Mantel-Haenszel
trend test p=0.63).
Incidence of biopsy-proven rejection
A total of 103 (27%) LDLT recipients had at least one biopsy-proven rejection episode and
58 (27%) DDLT recipients had at least one biopsy-proven rejection episode (P=0.97) (Table
3). A total of 143 biopsy-proven rejection episodes were reported in LDLT recipients vs. 73
biopsy-proven rejection episodes in DDLT recipients. These results demonstrated a similar
rate of biopsy-proven rejection in the LDLT and DDLT groups, with or without Center A.
Incidence of first vs. recurrent episodes of clinically treated and/or biopsy-proven
rejection
LDLT and DDLT recipients experienced a similar incidence of initial episodes of biopsy-
proven rejection (Table 3). Interestingly, there was a similar proportion of recipients who
were clinically treated for a single episode of rejection (with or without confirmation by
liver biopsy) in LDLT and DDLT recipients. However, more LDLT recipients were
clinically treated for second and third episodes of rejection when compared to the DDLT
group (Table 3, P=0.006). Taken together, these data suggest that there was a lower
threshold for empirical treatment of clinically suspected recurrent rejection in LDLT
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recipients. However, after excluding Center A, LDLT recipients were not significantly more
likely to be clinically treated for recurrent rejection (P=0.63). The data do not provide an
identifiable reason or other relevant information to explain and/or justify treatment without
biopsy.
Time to first rejection
The majority of first acute rejection episodes were diagnosed in the first year after
transplantation (Figures 1 and 2). Consistent with the analyses above, the time to first
clinically treated rejection (Figure 1) was shorter in LDLT than DDLT recipients when all
nine sites were included (P=0.044), but not when Center A was excluded from LDLT group
(P=0.63). For biopsy-proven rejection (Figure 2), the time from transplant to first occurrence
was similar for LDLT and DDLT recipients (P=0.81), whether or not Center A was included
(P=0.71).
Variables associated with the incidence of biopsy-proven rejection
In a multivariable Cox regression model of time to biopsy-proven rejection, we observed a
higher relative risk of rejection for patients with autoimmune liver disease (HR=1.87,
P=0.038) and for patients with HCV diagnosis (HR=1.53, P=0.011). Hispanic patients had a
higher risk of rejection compared to non-Hispanic patients although the difference was not
statistically significant (HR=1.41, P=0.066) (Table 4 Model A). Similar to the Kaplan-Meier
analysis in Figure 2, no significant difference was found in the overall adjusted risk of
biopsy-proven rejection between LDLT and DDLT in Model B (P=0.75). In addition, the
lack of a significant interaction (P=0.77) between LDLT and autoimmune disease suggested
that there were no alloimmune-related benefits of LDLT compared to DDLT. Antibody
induction therapy in the immediate post-transplant period was not associated with biopsy-
proven rejection (P=0.20) or a differential immunological advantage in LDLT vs. DDLT
recipients (interaction P=0.38).
When cold ischemia time was added to the Cox regression model, we observed that the risk
of biopsy proven rejection for all liver transplant recipients was higher with longer cold
ischemia time (HR=1.04 per hour, P=0.050) (Table 4 Model C). When cold ischemia time
was added to the model, for a given cold ischemia time, LDLT was associated with a higher
risk of rejection than DDLT, although the difference did not meet the traditional level of
statistical significance (HR=1.63, P=0.10). Because cold ischemia time is generally much
longer for DDLT than for LDLT recipients (DDLT: median 465 minutes, range 75 to 1230
minutes; LDLT: median 53 minutes, range 10 to 840 minutes; P<0.001), the cold ischemia
time and LDLT effects must be interpreted simultaneously to estimate the risk of rejection
for recipients of the average LDLT compared to the average DDLT. Figure 3 shows this
relationship by plotting the relative risk of rejection for LDLT and DDLT transplants by
cold ischemia time. For example, the risk of rejection for an LDLT with 50 minutes of cold
ischemia time is similar to that of a DDLT with 380 minutes of cold ischemia time. After
adjusting for transplant type (LDLT vs. DDLT), longer cold ischemia time was associated
with increased risk of rejection (HR=1.10; P=0.01) (Table 4 Model D).
Rejection as a cause of graft loss or death
Of the 380 LDLTs, 117 experienced graft failure (KM probabilities: 20% by one year and
26% by three years). Six of 117 (5.1%) were reported to be associated with acute rejection
and one was due to chronic rejection. Of the 213 DDLTs, 55 experienced graft failure (KM
probabilities: 13% by one year and 25% by three years). None was reported to be associated
with acute rejection and one of 55 (1.8%) was due to chronic rejection. Unadjusted rates of
graft failure due to rejection were not significantly different between LDLT and DDLT
grafts (P=0.16).
Shaked et al. Page 5














We hypothesized that LDLT, when compared to DDLT, presents a unique inflammatory and
immunological setting that may affect immediate and long term alloimmune response. This
hypothesis was based on observations seen after living donor kidney transplantation in
which the live donor kidney is associated with favorable immunological and function
outcomes in the short and long term. Experimental and clinical observations suggest that
these advantages are attributable to donor quality, a relatively short period of cold ischemia
resulting in less injury from proinflammatory mediators, and to shared HLA haplotypes in
the majority of biologically related living donor kidney transplants (12-14). These variables,
in aggregate, contribute to better outcomes of kidney transplants performed using living
donors.
Similar issues may affect outcomes after transplantation of living donor liver allografts, with
the addition of a few important processes that are unique to the regenerating liver lobe. In
this context, we have identified four principal differences between LDLT and DDLT,
including those related to donor quality, the proinflammatory response affected by cold
ischemia, upregulated genomic activity as a result of liver regeneration, and better HLA
matching between donors and recipients. The aims of the current study were to explore, in
aggregate, the effects of these considerations on immune-related injury and survival of the
allograft in the short and long term after transplantation. We expected that these injuries
would be expressed in the clinical setting by the rates of acute rejection and/or graft loss
related to rejection. It is important to recognize that whereas these clinical outcomes would
not be attributable to a particular pre-transplant liver diagnosis, observation of a significant
difference in the rejection pattern between LDLT vs. DDLT would suggest that
immunosuppression protocols should be individualized in each setting to reduce the rates of
rejection and consequent graft loss. Better understanding of mechanisms and reducing
episodes of rejection are beneficial to patients since the treatment options for ACR are
associated with harmful outcomes that are related to the side effects of higher doses of
calcineurin inhibitors, steroids, and/or antibody therapy.
In adult recipients, LDLT is done under elective circumstances in which a healthy individual
undergoes removal of a lobe (usually the right lobe) of the liver. This is very different than
the brain dead donor that has experienced massive physiological and hormonal shifts, all of
which may be harmful to the liver (15). In addition, the living donor procedure is well
coordinated with the recipient operation, resulting in short cold ischemia time (16).
Preliminary genomic studies on liver biopsies taken from brain dead and living donor liver
donors demonstrate differences in regulation of proinflammatory response genes, which may
reflect the differential degree of liver injury or relate to the duration of cold ischemia (17,
18). Lessons learned in the deceased donor kidney transplant setting demonstrate that donor-
related injury and prolonged cold ischemia time are associated with a higher rate of delayed
graft function, and a subsequent increase in the frequency of ACR (19). This may be
different for recipients of kidney from a living donor, in whom cold ischemia and delayed
graft function may not expose the organ to a higher rate of ACR (20).
The similar rate of biopsy-proven rejection in our large groups of LDLT and DDLT
recipients suggest that the impact of the type of allograft on the frequency of ACR is
relatively minimal. Proinflammatory pathways may be activated by brain death, cold
ischemia, or during induction of liver regeneration. Whereas the clinical outcomes appear to
be the same, we are able to clearly demonstrate in both groups an important association
between the length of cold ischemia and the frequency of biopsy proven ACR. However, it
appears that the living donor liver is far more susceptible to prolonged cold ischemia than
the deceased donor allograft. We have given the example that a LDLT allograft with only 50
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minutes of cold ischemia has the same risk of ACR as a DDLT allograft with 380 minutes of
cold ischemia time. The potential for development of ACR increases in both groups as
organs are kept under cold preservation. It was expected that exposure to a shorter cold
ischemia time in the LDLT setting would be associated with decreased cold ischemia-
mediated injury, manifested via differential regulation of proinflammatory pathways. In
theory, decreased proinflammation may affect the pattern of alloimmune response.
However, other variables must be considered including the initiation of regenerative
pathways in the LDLT allograft, which may also have some impact on alloimmunity. We
suggest that the net result of these processes should be taken into consideration when
correlating cold ischemia time and ACR in the LDLT and DDLT settings. A practical
interpretation of these clinical data strongly suggests that all liver allografts should be
exposed to the shortest possible period of cold ischemia, which may in turn be associated
with a reduced incidence of ACR, and avoid potential harmful immune and non-immune
consequences such as chronic rejection and recurrence of the primary liver disease.
It has been well established that liver regeneration starts within minutes after partial
hepatectomy and is associated with upregulation of cell cycle genes (21, 22). Recent
genomic analysis of deceased donor and living donor liver biopsy done within one hour after
reperfusion demonstrated additional differential regulation of proinflammatory and immune
response gene expression (6, 18). Microarray analysis revealed significant changes in the
activation and deactivation of multiple chemokine and interleukin genes, adhesion
molecules, and antigen processing genes. While similarities existed between DDLT and
LDLT, each group also expressed unique patterns of up- and down-regulation of sets of
proinflammatory and immunoregulatory genes. Intuitively, the differences in
proinflammatory and immune gene activation in LDLT vs. DDLT should have been
associated with a differential activation of alloimmune response, and consequently, a
difference in the pattern and rate of rejection. In the clinical setting, however, these
differences were not seen either in the early post-transplant period or at one and three years.
It appears that the immunosuppression strategies employed were similarly effective in
preventing biopsy-proven rejection in the two groups.
The potential beneficial effect of more similar HLA identity in the living donor setting has
not been proven for adult or pediatric patients receiving partial liver allografts from blood
relatives (23, 24). Similarly, we are unable to comment whether this variable has any short
or long term impact in living donor liver recipients, and are cognizant that such data may
require analysis of larger cohorts of patients.
Analysis of our data reaffirmed previous observations related to the impact of the etiology of
the underlying liver disease on biopsy-proven rejection with respect to autoimmune disease.
In addition, we now show that hepatitis C virus infection as a cause of liver failure is a
significant predictor of rejection.
Our study revealed interesting findings related to the practice of treating rejection in the
participating centers. The gold standard for the diagnosis of rejection requires biopsy
confirmation. However, we observed that 19% and 11% of LDLT and DDLT recipients,
respectively, were treated for rejection based on clinical judgment alone by the transplant
team without a confirmatory biopsy. Even excluding one site where 91% of LDLT
recipients had clinically treated rejection (Center A), 9% and 6%, respectively, were treated
without biopsy.
Overall, a significantly higher proportion of LDLT (vs. DDLT) recipients had clinically
treated rejection, but this difference also varied greatly among centers. When we excluded
Center A, the proportion of LDLT recipients with clinically treated rejection was identical to
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that for DDLT (35%). Similarly, the times to first clinically treated rejection were the same
for LDLT and DDLT when Center A was excluded. Thus, at some centers, there may be a
lower threshold for treating LDLT recipients for rejection in response to fluctuating elevated
liver enzymes, and/or reluctance to perform a biopsy in the setting of a partial allograft. We
conclude that these represent center-specific practices. It remains to be seen whether such
divergences in practice will be observed in the prospective A2ALL cohort study, in which
immunosuppression is more protocol-driven than in the current retrospective study.
There are some limitations of this retrospective observational cohort study. We did not have
detailed information (e.g., drug dosages and blood levels) regarding baseline
immunosuppression practices beyond the drug regimens used at discharge from the
transplant hospitalization and those used for maintenance immunosuppression at the time of
rejection episodes. We did not have information on the specific indications for treatment of
clinically suspected rejection, such as laboratory values or exclusionary diagnostic studies
that were obtained prior to initiation of anti-rejection therapy. Since there was no central
pathology reading, there may have been differences in histological interpretations among
centers. Despite these shortcomings, our results present a picture of clinical practice on the
basis of information available to treating physicians.
Based on the results reported here, we conclude that there is no demonstrable
immunological advantage under current standard immunosuppression and clinical practices
for recipients who undergo LDLT. The current results do not support the use of different
immunosuppression protocols for LDLT vs. DDLT recipients. In either setting, a beneficial
impact on immune related outcomes may be achieved by minimizing the duration of cold
ischemia of the allograft.
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Time interval from transplant to first clinically treated rejection for LDLT (with and without
Center A) and DDLT recipients.
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Time interval from transplant to first biopsy-proven rejection for LDLT and DDLT
recipients.
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Relative risk of biopsy-proven rejection for LDLT and DDLT transplants by cold ischemia
time. The reference (hazard ratio = 1.0) is LDLT with 50 minutes of cold ischemia time. The
hazard ratios are shown for the 5th to 95th percentiles of cold ischemia time within LDLT
and DDLT. In addition, the lines are thicker in the regions of the 25th to 75th percentiles of
cold ischemia time.
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or N (%) P-value
*
Recipient Age 49.3 (10.7) 50.9 (9.8) 0.06
Recipient Gender (% Male) 219 (58%) 127 (60%) 0.64
Recipient Race (% White) 344 (91%) 187 (88%) 0.59
Recipient Ethnicity (% Non-Hispanic) 306 (81%) 173 (81%) 0.84
Diagnosis at Listing and Enrollment (more than one diagnosis
per patient possible)
    Hepatitis C virus-related (HCV) cirrhosis 181 (48%) 99 (46%) 0.79
    Hepatocellular carcinoma (HCC) 56 (15%) 33 (15%) 0.80
    Alcoholic cirrhosis 52 (14%) 31 (15%) 0.77
    Cholestatic liver disease 70 (18%) 39 (18%) 0.97
    Non-cholestatic cirrhosis (other than HCV and alcoholic
cirrhosis)
80 (21%) 48 (23%) 0.67
    Metabolic disease 11 (3%) 7 (3%) 0.79
    Biliary atresia 3 (1%) 0 (0%) 0.56
    Malignancy other than HCC 11 (3%) 5 (2 %) 0.69
    Autoimmune liver disease 19 (5%) 11 (5%) 0.93
    Other 10 (3%) 5 (2%) 0.83
Immunosuppressant Medications
    Antibody induction 52 (14%) 26 (12%) 0.61
    Steroids 371 (98%) 207 (97%) 0.74
    Calcineurin Inhibitor 365 (96%) 202 (95%) 0.49
        Cyclosporine 61 (16%) 34 (16%) 0.98
        Tacrolimus 308 (81%) 174 (82%) 0.85
    Third agent 275 (72%) 143 (67%) 0.18
*
P-values are based on two-sample t-tests for continuous variables, and from chi-square tests for dichotomous variables.
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Table 2
Number and Percent of Patients with Clinically Treated and Biopsy-Proven Rejection Episodes, by Transplant
Center.
Number of Transplants Clinically Treated Rejection Episodes Biopsy-Proven Rejection Episodes
Transplant Center LDLT DDLT LDLT (N=380) DDLT (N=213) LDLT (N=380) DDLT (N=213)
A 70 40 64 (91%) 20 (50%) 21 (30%) 7 (18%)
B 25 10 19 (76%) 6 (60%) 9 (36%) 3 (30%)
C 28 42 18 (64%) 8 (19%) 9 (32%) 7 (17%)
D 20 10 9 (47%) 3 (30%) 7 (37%) 3 (30%)
E 24 29 10 (42%) 7 (24%) 10 (42%) 7 (24%)
F 59 25 20 (34%) 17 (68%) 19 (33%) 17 (68%)
G 63 23 20 (32%) 9 (39%) 20 (32%) 8 (35%)
H 63 18 10 (16%) 7 (39%) 6 (10%) 5 (28%)
I 31 16 4 (13%) 3 (19%) 2 (7%) 1 (6%)
Chi-square Test for Centers P<0.0001 P=0.0012 P=0.0034 P=0.0002
Chi-square Test for Centers
excluding Center A
P<0.0001 P=0.0015 P=0.0017 P=0.0005
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Table 3
Number of Patients by Number of Clinically Treated or Biopsy-Proven Rejection Episodes
Clinically Treated Biopsy-Proven
# Rejection Episodes LDLT (N=380) DDLT (N=213) LDLT (N=380) DDLT (N=213)
0 206 (54%) 133 (62%) 277 (73%) 153 (72%)
1 105 (28%) 59 (28%) 72 (19%) 44 (14%)
2 53 (14%) 18 (8%) 25 (7%) 13 (6%)
≥ 3 16 (4%) 3 (1%) 6 (2%) 1 (0.5%)
Total # with Any Rejection
* 174 (46%) 80 (38%) 103 (27%) 58 (27%)
Chi-square Test for % with Any Rejection in LDLT vs. DDLT P=0.052 P=0.97
Mantel-Haenszel Trend Test P=0.006 P=0.65
*
Excluding Center A, the respective numbers (%) of clinically treated rejection episodes were 110/310 (35%) for LDLT and 60/173 (35%) for
DDLT (chi-square p=0.86 and Mantel-Haenszel trend test p=0.63). Excluding Center A had no effect on the statistical comparisons between LDLT
and DDLT for biopsy-proven rejection episodes: the respective numbers (%) of biopsy-proven rejection episodes were 82/310 (26%) for LDLT and
51/173 (29%) for DDLT (chi-square p=0.48 and Mantel-Haenszel trend test p=0.78).
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Table 4
Multivariable Cox Regression Models of Time to Biopsy-Proven Rejection
*
Hazard Ratio 95% Confidence Limits P-Value
Model A:
Autoimmune liver disease 1.87 1.04 3.39 0.038
HCV diagnosis 1.53 1.10 2.13 0.011
Hispanic 1.41 0.98 2.02 0.066
Model B (includes all covariates in Model A, plus LDLT vs. DDLT):
LDLT 0.95 0.69 1.31 0.752
Model C (includes all covariates in Model A, plus cold ischemia time):
Cold ischemia time (per hour) 1.04 1.00 1.09 0.050
Model D (includes all covariates in Model A, plus LDLT vs. DDLT and cold ischemia time):
LDLT 1.63 0.90 2.95 0.105
Cold ischemia time (per hour) 1.10 1.02 1.17 0.010
*
Variables tested but not significant included recipient age, gender, race, diagnosis of hepatocellular carcinoma and cholestatic liver disease,
transplant year, and antibody induction, and donor age.
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